No Detail Found!

Immunohistochemical Expression of Glypican-3 in Hepatocellular Carcinoma.

Author(s)
Syed Salman Ali Armed Forces Institute of Pathology (AFIP), National University of Medical Sciences (NUMS), Rawalpindi, Pakistan
Javeria Shaukat Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Rabia Ahmed Armed Forces Institute of Pathology (AFIP), National University of Medical Sciences (NUMS), Rawalpindi, Pakistan
Iqbal Muhammad Armed Forces Institute of Pathology (AFIP), National University of Medical Sciences (NUMS), Rawalpindi, Pakistan
Abstract
Objective: To determine the frequency of immunohistochemically expression of Glypican-3 in hepatocellular carcinoma on liver biopsies. Study Design: Descriptive cross-sectional study. Place and Duration of Study: Department of Histopathology, Armed Forces Institute of Pathology (AFIP), Rawalpindi, from Jun 2015 to Jun 2016. Material and Methods: A total of 55 liver biopsies from the patients of hepatocellular carcinoma were included in the study. Age, gender, tumor grade and immunohistochemically expression of glypican-3 were noted. The data were analyzed by SPSS version 21. Mean and SD were calculated for numerical variables such as age. Percentages and frequencies were calculated for gender, tumor grade and immunohistochemically expression of glypican-3. The data collected for study were statistically analyzed using chi-square test. Results: Out of 55 patients of hepatocellular carcinoma, 44 (80%) were males and 11 (20%) were females. The age of the patients was between 41 and 80 years with an average age of 59.7 years and standard deviation of ± 8.8. Out of 55 cases, 32 cases (58.2%) were well differentiated, 18 cases (32.7%) were moderately differentiated and 5 cases (9.1%) were poorly differentiated. Forty-eight cases of hepatocellular carcinoma (87.3%) showed positivity for glypican-3 while 7 cases (12.7%) were negative. A significant statistical association was not seen among age, gender, tumor grade and glypican-3 expression, p-value being >0.05. Conclusion: The high expression of glypican-3 in hepatocellular carcinoma suggests its diagnostic utility and also its value in distinguishing hepatocellular carcinoma from other hepatic lesions. As antiglypican-3 therapy is currently under clinical evaluation, it might be useful as a therapeutic target in glypican-3 positive hepatocellular carcinoma cases.
Publication Details
Page(s) 692-696
DOI DOI not available
Published Journal: Pakistan Armed Forces Medical Journal, Volume: 68, Issue: 4, Year: 2018

Request the full text from PASTIC

References
ZhuRX,SetoWK,LaiCL,YuenMF, 2016.Epidemiology of hepatocellular carcinoma in the asia-pacific region,Gut Liver 10 332 -9
ButtAS,HamidS,WadalawalaAA,GhufranM,JavedAA,FarooqO, 2013.Hepatocellular carcinoma in Native South Asian Pakistani population; trends, clinico-pathological characteristics & differences in viral marker negative & viral- hepatocellular carcinoma,BMC Res Notes 6 137 -
FilmusJ,CapurroM, 2013.Glypican-3: A marker and a therapeutic target in hepatocellular carcinoma,FEBS J 280 2471 -6
KewMC, 2010.Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma,Pathol Biol 58 273 -7
ChenJH,WangYY,LvWB,GanY,ChangW,TianNN, 2016.Effects of interactions between environmental factors and KIF1B genetic variants on the risk of hepatocellular carcinoma in a Chinese cohort,World J Gastroenterol 22 4183 -90
TorreLA,BrayF,SiegelRL,FerlayJ,Lortet-TieulentJ,JemalA, 2015.,2012. CA Cancer J Clin 65 87 -108
GohGB,ChangPE,TanCK, 2015.Changing epidemiology of hepatocellular carcinoma in Asia,Best Pract Res Clin Gastroenterol 29 919 -28
AhmadZ,ArshadH,FatimaS,IdreesR,Ud-DinN,AhmedR, 2013.Gastrointestinal, liver and biliary tract pathology: A histopathological and epidemiological perspective from Pakistan with a review of the literature,Asian Pac J Cancer Prev 14 6997 -7005
El-SeragHB, 2012.Epidemiology of viral hepatitis and hepatocellular carcinoma,Gastroenterology 142 1264 -73
YangJD,RobertsLR, 2010.Hepatocellular carcinoma: A global view,Nat Rev Gastroenterol Hepatol 7 448 -58
ZaakookM,AyoubM,SinnaEA,El-Sheikh S, 2013.Role of glypican-3 immunocytochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver utilizing fine needle aspiration cytology,J Egypt Natl Canc Inst 25 173 -80
YanB,WeiJ,QianY,ZhaoX,ZhangW,XuA, 2011.Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma,Ann Diagn Pathol 15 162 -9
FengM,HoM, 2014.Glypican-3 antibodies: A new therapeutic target for liver cancer,FEBS Lett 588 377 -82
WangFH,YipYC,ZhangM,VongHT,ChanKI,WaiKC, 2010.Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy,J Clin Pathol 63 599 -603
AnatelliF,ChuangST,YangXJ,WangHL, 2008.Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy,Am J Clin Pathol 130 219 -23
WangHL,AnatelliF,ZhaiQJ,AdleyB,ChuangST,YangXJ, 2008.Glypican-3 as a Useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions,Arch Pathol Lab Med 132 1723 -8
HoM,Kim H, 2011.Glypican-3: A new target for cancer immunotherapy,Eur J Cancer 47 333 -8
KringsG,RamachandranR,JainD,WuTT,YehMM,TorbensonM, 2013.Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma,Mod Pathol 26 782 -91
0

Citations

0

Downloads

59

Views